JMP keeps Boston Scientific at strong buy

Boston Scientific Corp. was maintained at a strong buy rating by JMP Securities analyst Robert C. Faulkner. The Wall Street Journal article on safety concerns for drug-eluting stents highlights an issue already visible in stent market performance, according to the analyst. Drug-eluting stent usage was up slightly sequentially last quarter, from 88% of total U.S. stents in the fourth quarter of 2005, to 89% in the first quarter of 2006. The analyst projects zero growth in the second quarter of 2006. Shares of the Natick, Mass.-based medical device company were down 50 cents, or 2.62%, at $18.61 on volume of 26,197,100 shares versus the three-month running average of 13,174,900 shares. (NYSE: BSX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.